'김갑성' 기자의 전체기사
-
FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®…
This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 -- Echosens, the leader in non-invasive liver diagnostics, is announcing today that the U.S. Food and Drug Administration's (FDA's) Center for Drug Evaluation and Research (CDER), Office of New Drugs has accepted the company's Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography (FibroScan®) as a reasonably likely su
- 김갑성 기자
- 2025-09-08 18:00
-
Remplir™ Study Delivers Compelling 81% Success Rate
Data to support US sales roll out and EU + UK regulatory submissions Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. Real World Evidence (RWE) patient data collected in the study confirms Orthocell's nerve repair product, Remplir, as the ideal medical device for connecting severed nerves, protecting damaged nerves, or capping nerve ends after amputation. The data demonstrated: 83.9% of muscles innervated by repaired nerves achieved functional motor recovery. 89.5% of nerv
- 김갑성 기자
- 2025-09-08 17:32
-
Servier acquires potential treatment for Fragile X syndrome, th…
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA Acquisition strengthens Servier's neurology pipeline in line with its 2030 strategy SURESNES, France, Sept. 8, 2025 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition
- 김갑성 기자
- 2025-09-08 15:49
-
Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital He…
GUANGZHOU, China, Sept. 8, 2025 -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue of RMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year-on-year to RMB 150 million. The expansion in net profit significantly outpaced top-line growth, reflecting improved profitability and greater operating leverage. The company also delivered robust cash flow. Operating cash flow reached RMB 300 million, up 111% from the prior year, while free cash flow tota
- 김갑성 기자
- 2025-09-08 15:35
-
Siriraj × MIT Hacking Medicine 2025 Now Open for Applications A…
BANGKOK, Sept. 8, 2025 -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place from October 31 to November 2, 2025. Applications are now open for participants across Southeast Asia. The event aims to bring together multidisciplinary professionals to develop innovative solutions in medical treatment and healthcare services, all within an ecosystem of hospitals, faculties of engineering and accountancy, the private sector, investors, and incubation program
- 김갑성 기자
- 2025-09-08 14:39
-
Merz Aesthetics® Tops Best Workplaces in Asia™ 2025 List b…
SINGAPORE, Sept. 8, 2025 -- Merz Aesthetics, the world's largest dedicated medical aesthetics business has officially been recognized as No.1 under Best Workplace in Asia 2025 in the Small & Medium Business category by Great Place To Work, celebrating its commitment to a truly inclusive, people-first culture. With a proud 117-year heritage as a family-owned business, Merz Aesthetics has always taken the long view of success - investing in people, advancing innovation, and nurturing a culture of respect, integrity, and trust. This recognition underscores the company'
- 김갑성 기자
- 2025-09-08 12:50
-
Sirnaomics Announces Strategic Equity Investment by Bloom…
HONG KONG, Sept. 7, 2025 -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a strategic investment agreement with Bloomage Biotech (stock code: 688363.SH) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited. Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics' strategic placement at HKD 12 per
- 김갑성 기자
- 2025-09-08 12:15
-
DRONTECH ASIA 2025 RETURNS TO KUALA LUMPUR, SHOWCASING CUTTIN…
[ 메디채널 김갑성 기자 ] The region's premier drone and UAV exhibition and conference enters its second edition with strong global participation, a high-level opening by Malaysia's Deputy Minister of Investment, Trade and Industry, and a mission to drive ASEAN's leadership in unmanned technologies. KUALA LUMPUR, Malaysia, Sept. 8, 2025 -- Aerosea Exhibitions Sdn Bhd is proud to announce the return of DronTech Asia 2025, the region's premier drone and UAV exhibition and conference, taking place from 30 September to 2 October 2025 at MITEC, Kuala Lumpur, under the theme "Pushing the Bounda
- 김갑성 기자
- 2025-09-08 10:40
-
Wel-Bloom and New-In to Exhibit at Vitafoods Asia 2025, Advanc…
NEW TAIPEI CITY, Sept. 8, 2025 -- As a leader of jelly supplements, Wel-Bloom Biotech will join its affiliated company New-In in exhibiting at Vitafoods Asia 2025, held in Bangkok, Thailand from September 17 to 19, 2025. The showcase will feature a variety of technologies and Taiwan-sourced ingredient applications, presenting an upgraded one-stop CDMO service that reflects the group's commitment to both nutritional innovation and sustainable manufacturing. Having developed health supplements for brand partners in over 60 countries worldwide, Wel-Bloom is recognized for its high level o
- 김갑성 기자
- 2025-09-08 10:30
-
Epigenic Therapeutics Announces Completion of $60 Millio…
SHANGHAI, Sept. 8, 2025 -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry. This round of funding will primarily support the ongoing clinical development of EPI-003 for chronic hepatitis B functional cure and EPI-001 for hypercholesterolemia treatment. Additionally,
- 김갑성 기자
- 2025-09-08 10:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분